mapOur Location
Check on Maps
mapContact Us
This email address is being protected from spambots. You need JavaScript enabled to view it.
 

Product

 

Therapeutic
Area

Innovator
Launch
Year

2009
Sales

Biosimilar
Launch
Year (US)

Percent
Market

Target
Sales at
Peak

Partner/
Retain

Neulasta

Neutropenia

2002

$3.3B

2016

25%

$0.8B

$0.8B Retain

Enbrel

RA

1998

$6.6B

2016

25%

$1.7B

Partner

Rituxan

Non-
Hodgkin's
Lymphoma
RA

1997

$5.6B

2018

25%

$1.0B

Partner

Herceptin

Breast
Cancer

1998

$4.7B

2018

25%

$.8B

Partner

Avastin

Colorectal
Cancer

2004

$5.7B

2019

25%

$1.4B

Partner